Ford Recalls Over 1 Million Vehicles in the US for Rearview Camera Issues

Published 2 days agoF

Ford Recalls Over 1 Million Vehicles in the US for Rearview Camera Issues

Ford Motor Company is set to recall more than 1 million vehicles in the United States due to problems with rearview cameras that could potentially increase the risk of a crash. This recall affects around 1,075,299 vehicles from the 2021 to 2025 model years, encompassing a wide range of models including the Bronco, F-150, Edge, Escape, Corsair, Expedition, and several others, as reported by Reuters.

The issue stems from a software glitch in the accessory protocol interface module, which may lead to the rearview camera image either delaying, freezing, or not displaying at all. This is a significant concern as it can impair driver visibility when the vehicle is in reverse. The automaker plans to resolve the issue by issuing a free over-the-air software update for the affected vehicles.

Ford has announced that owners will be notified of the recall via letters by June 16, 2025, with an additional letter to be sent when the software fix is available in the third quarter of 2025. This recall comes amid heightened scrutiny following a previous situation where Ford incurred a US civil penalty of up to $165 million, levied by the National Highway Traffic Safety Administration, for delayed recalls of faulty rearview cameras.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Gilead Pledges HIV Prevention Drug for Low-Income Nations Amid Funding Concerns

Gilead Pledges HIV Prevention Drug for Low-Income Nations Amid Funding Concerns

10 minutes agoGILD

Gilead Sciences has confirmed its dedication to delivering lenacapavir, an innovative HIV prevention injection, to low-income countries even though funding remains uncertain. Lenacapavir has shown almost 100% efficacy in clinical trials and is anticipated to secure FDA approval by June 19, 2025. With the backing of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund, the drug is slated for rollout by early 2026, Reuters reported. To enhance accessibility, Gilead plans to offer lenacapavir at production cost for two to three years, aiming for a pricing point between $100 and $120 annually in these countries. Despite this commitment, challenges loiter due to potential funding reductions in U.S. international aid, including PEPFAR. Organizations such as the Global Fund are attempting to rally the necessary support, yet the threat of funding cuts persists. To further facilitate global access, Gilead has partnered with six generic manufacturers through royalty-free licensing agreements. This move is set to broaden the availability of lenacapavir across 120 low- and middle-income countries. However, the long-term success of these efforts is contingent upon securing consistent global funding and collaboration.

Tesla and Tech Giants Tumble Amid New Tariff Concerns

Tesla and Tech Giants Tumble Amid New Tariff Concerns

25 minutes agoTSLA

U.S. stock index futures took a hit on April 3, 2025, as new tariff policies sparked uncertainty across the markets. The Nasdaq 100 futures dropped by 3.88%, with tech heavyweights feeling the pressure. Apple shares led the decline, plunging 7.6%, followed by Amazon at 6.4%, Meta Platforms at 4.7%, Alphabet at 2.9%, and Microsoft at 2.7%, according to itiger.com. Tesla saw its stock fall by 6% after the announcement of newly imposed tariffs by President Donald Trump. These tariffs included a 10% levy on all imported goods, with steeper penalties for certain countries such as the European Union at 20% and Cambodia at 49%. The changes pose potential challenges for Tesla's global operations, notably its Gigafactory in Shanghai, where policy shifts could impact production costs and margins. The broader market reacted with a global selloff, affecting major Asian and European indices, demonstrating widespread investor concern. Forbes noted the turbulence, highlighting fears of a potential trade war that could disrupt the tech sector significantly. These tariffs might escalate production costs and create supply chain challenges for companies like Tesla that depend on international manufacturing.

Sanofi Shares Dip After Mixed Itepekimab Trial Results

Sanofi Shares Dip After Mixed Itepekimab Trial Results

Sanofi's shares saw a decline after the company announced mixed results from studies involving its investigational drug, Itepekimab. Despite demonstrating effectiveness in clinical trials, the market reacted with caution. Itepekimab, tested in adults with asthma and COPD, showed promising outcomes but below some expectations. The Phase 2 trial results revealed that Itepekimab reduced asthma control loss events by 58% compared to a placebo in a study involving 296 adults with moderate-to-severe asthma. In a similar trial for COPD, targeted at former smokers with moderate-to-severe cases, Sanofi reported a 51% reduction in exacerbation rates. Despite these figures, the mixed responses and potential challenges facing the drug may have influenced investor sentiment, according to reports from Healio. Sanofi’s strategies continue to focus on developing Itepekimab's potential in treating respiratory conditions effectively. Currently, Sanofi's shares reflect a slightly adjusted market position at $52.35, with a subtle change of $0.36 from the prior close. While these studies underscore Itepekimab's promise, they also emphasize the risks and variability involved in pharmaceutical advancements.

Marvell Technology's Data Center Revenue Climbs as Networking Segment Struggles

Marvell Technology's Data Center Revenue Climbs as Networking Segment Struggles

2 hours agoMRVL

Marvell Technology announced robust growth in its data center segment for the first quarter of fiscal year 2025, with revenue soaring to $816 million. This marks an 87% increase compared to the same period last year and a 7% rise from the previous quarter. As reported by PR Newswire, this segment now contributes to 70% of Marvell's total revenue, fueled by rising demand for AI cloud applications and the introduction of custom AI compute programs. Conversely, the enterprise networking segment experienced significant challenges, with revenue dropping to $153 million, which represents a 58% year-over-year decrease. According to Nasdaq, these results stemmed from a weak demand environment and inventory adjustments. This segment now makes up 13% of Marvell's overall revenue, highlighting its diminished contribution as compared to the thriving data center business. Overall, Marvell's total revenue reached $1.16 billion for the quarter, surpassing analyst forecasts slightly, as noted by Investopedia. Looking ahead, the company anticipates a mid-single-digit sequential revenue growth in the upcoming quarter, driven by a scale-up in custom AI silicon. Despite the struggles in networking, Marvell's performance underscores its strong foothold in the burgeoning data center market.